Thursday, 8th February 36th Lorne Cancer Conference 2024

Intro by Richard Lock, Chair of the Lorne Cancer Organising Committee.

• Neuron-glial interactions in health and disease: from cognition to cancer - Michelle Monje
• Uncovering dynamic changes in Medulloblastoma associated vasculature in zebrafish. - Anne Karine Lagendijk
• The immune infiltrate in breast cancer and relevance for prognosis and checkpoint inhibition. - Sherene Loi
• A novel first-in-class anti-fibrotic blunts tumour desmoplasia, rewires stromal signalling and augments gemcitabine response and survival in pancreatic cancer - Thomas R. Cox
• Understanding how the tissue microenvironment directs cell fate in haematopoietic stem and progenitor cells - Elanor N Wainwright

• Blocking cancer-fibroblast mutualism inhibits estrogen-independent proliferation of endocrine therapy-resistant breast cancer - Andrea Bild
• Feed-forward stimulation of CAMK2 by the oncogenic pseudokinase PEAK1 generates an ‘actionable’ signalling axis in triple negative breast cancer - Roger Daly
• Developing physiological models to target the unique metabolic wiring in TNBC - Jeff Holst

Flash Talks

1. Learning transcriptional and regulatory dynamics driving cancer cell plasticity using neural ODE-based optimal transport - Shabarni Gupta

2. High affinity T-cell receptors against HLA-presented cancer antigens using single-cell RNA sequencing for precision T-cell receptor therapy - Gwo Yaw Ho

3. Identification of aberrant luminal progenitors and mTORC1 as a potential breast cancer prevention target in BRCA2 mutation carriers - Rachel Joyce

4. Intrinsic Effects of Germline BRCA1 Mutations on Activated Peripheral Human T Cell Phenotypes - Jasmine Kay

5. PRMT5 Inhibitor's (GSK3266595) Role in Alternative Splicing May Underpin its Inhibitory Effect in Pancreatic Ductal Adenocarcinoma - Michael Lee

6. Developing novel EphA3-targeted CAR T cells for the treatment of glioblastoma - Leesa Lertsumitkul

7. Deciphering the cell-of-origin in BRCA1-derived ovarian cancer - Laura Marruecos

• A multi-omically guided approach to the treatment of diffuse midline gliomas. (NOT ATTENDING) - Izac J. Findlay
• Intrinsic Effects of Germline BRCA1 Mutations on Activated Peripheral Human T Cell Phenotypes - Jasmine Kay
• Learning transcriptional and regulatory dynamics driving cancer cell plasticity using neural ODE-based optimal transport - Shabarni Gupta
• High affinity T-cell receptors against HLA-presented cancer antigens using single-cell RNA sequencing for precision T-cell receptor therapy. - Gwo Yaw Ho
• Deciphering the cell-of-origin in BRCA1-derived ovarian cancer - Laura Marruecos
• Identification of aberrant luminal progenitors and mTORC1 as a potential breast cancer prevention target in BRCA2 mutation carriers - Rachel Joyce
• PRMT5 Inhibitor’s (GSK3266595) Role in Alternative Splicing May Underpin its Inhibitory Effect in Pancreatic Ductal Adenocarcinoma - Michael Lee
• Developing novel EphA3-targeted CAR T cells for the treatment of glioblastoma    - Leesa Lertsumitkul
• Characterization of the effects of H3K27M variants on the DNA-damage response in diffuse midline glioma - Nicolas Poux
• Harnessing the nucleolar stress response in cancer therapy - Junqi Pan
• Reprogramming of mRNA translation drives drug resistance in ovarian cancer - Stefano M Gallucci
• Friend or foe: deconstructing cancer-immune interactions using patient-derived tumour models - Janneke Grundemann
• Establishing patient-derived organoid cultures as a preclinical model to study and treat ovarian cancer - Carolina Lliberos
• Dissecting the pleotropic roles of subcellular JNK signalling in mammary development and breast cancer progression - Misaki S Clearwater
• Targeting mRNA processing to overcome resistance in melanoma - Arwa Alkaraki
• Use of novel discoidin domain receptor inhibitors as a potential anti-fibrotic in pancreatic cancer - Diana Schuhmacher
• Redefining Survival Outcomes in Lower Grade Glioma Using the New WHO Classification System     - Oluwaseun Fatunla
• Decoding Cellular Behaviour and Treatment Challenges at Different Sites of Melanoma Metastasis. - Veronica Aedo-Lopez
• Temporal resolution of the epithelial-mesenchymal transition and chemotherapy resistance: a deep learning-enhanced single-cell imaging approach - Felix V Kohane
• Characterising epithelial-to-mesenchymal transition in ovarian carcinosarcoma preclinical models to identify new targets for treatment - Anthony Hadla
• Patient-derived pancreatic cancer organoids for the identification of new treatment opportunities - Paul Nguyen
• Better Together? Targeting Epigenetic Vulnerabilities in AML through combined Menin and MYST Acetyltransferase Inhibition - Shellaina JV Gordon
• Investigating and isolating functionally distinct clonal populations in normal and malignant haematopoiesis - Kelsy Prest
• The temporal dynamics of cancer resistance - Christina Bui
• Identification of new combination therapies for high grade serous endometrial carcinoma using high throughput in vitro drug screening - Joe Polidano
• An in vivo functional genomic screen to identify genes involved in multiple myeloma tumour development - Duncan Hewett
• Paediatric Oncology Revolution: Unleashing Precision Medicine through Phosphoproteomics - Terry Lim
• Defining the role of mammary fibroblasts in tumour progression - Amelia De Smet
• Investigating cis-regulatory element control of lineage specification in the mammary gland - Serena R Kane
• Understanding how Cancer Cells Exploit Lysosomal Biogenesis to Promote Survival - Tara A Tigani
• Understanding changes in the immune microenvironment during the development of p53-deficient breast tumours with or without Brca1 loss - Xiaoyu Song
• Defining the extracellular matrix of adult and paediatric high grade glioma/glioblastoma - Zoe I Day
• Exploring the role of NRF2 and ferroptosis in oesophageal cancer - Zoe Nguyen
• CDK9 inhibition as a therapeutic strategy in advanced prostate cancer (NOT ATTENDING) - Razia Rahman
• Integrated personalised approaches identify novel molecular targets in rare Head and Neck Cancer - Patrick Bergsma
• Identifying and targeting FOLFIRINOX resistance mechanisms to improve outcomes in pancreatic cancer   - Katie Gordon
• Age-specific differences in a preclinical paediatric orthotopic model of rhabdomyosarcoma. - Jorren JK Kuster
• Elucidating causative mechanisms of late effects using a clinically relevant model of radiotherapy in the developing mouse brain - Aiden Boonnark
• Aptamer-Based Targeting of PD-L1-Positive sEVs: Enhancing Therapeutic Strategies for Immune Cell Tolerance - Satendra Jaysawal
• Developing novel nucleic acid based detection system for immunostaining of cancer tissues - Jasmine Catague
• Using intravital two-photon imaging to gain insights into T cell dynamics and the influence of the tumour microenvironment in mouse models of glioma. - Misty R Jenkins
• Engineered receptors T cell fusion constructs (TRuC) and peptide-MHC-I targeting chimeric antigen receptor (CAR) on T cells form native T cell receptor-like immune synapse morphology and cytotoxicity. - Misty Jenkins
• The role of ADAMTS1 in ovarian cancer progression and chemoresistance - Ruth M Escalona
• Eribulin reduces sunitinib resistance by reversing hypoxia and epithelial mesenchymal transition associated metabolic reprograming in preclinical human clear cell renal carcinoma model. - Nuzhat Ahmed
• Age-dependent changes in peripheral T cell phenotypes of early-stage breast cancer patients - Stefanie Stirl
• Understanding and hijacking the ubiquitin system in neuroblastoma - Ziyan Liu
• CD155 plays a dominant role in modulating NK cell activation - Tania Allin Vargas Pavia
• A metabolic atlas of aging (NOT ATTENDING) - Peter James Mullen
• Targeting lipid metabolism to overcome therapy resistance in lethal prostate cancer - Olivia J Lee
• Surfaceome and extracellular matrix analyses of diffuse midline glioma and implications for immune-oncology therapies - Bryce Thomas
• Repurposing an approved copper chelator to improve the therapeutic outcome in PDAC - Ellie TY Mok
• Sensitising the rare paediatric brain cancer pineoblastoma to chemotherapy and radiotherapy using DNA damage response inhibitors - Jessica Buck
• Leveraging multi-omics approach to examine the potential role of causative viruses in glioblastoma (NOT ATTENDING) - Bavani Gunasegaran
• Preclinical evaluation of ACVR1 inhibitor TP0184, as a single agent and in combination with irradiation and trametinib in Diffuse Midline Gliomas. - Maria Tsoli
• Determination of the effects of doxorubicin upon cellular growth and DNA integrity using MDA-MB 453 cell line (NOT ATTENDING) - Nageshwar Rao B